| Pharmaceutical Information |
| Drug Name |
Altretamine |
| Drug ID |
BADD_D00088 |
| Description |
An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. |
| Indications and Usage |
For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination. |
| Marketing Status |
approved |
| ATC Code |
L01XX03 |
| DrugBank ID |
DB00488
|
| KEGG ID |
D02841
|
| MeSH ID |
D006585
|
| PubChem ID |
2123
|
| TTD Drug ID |
D02LPF
|
| NDC Product Code |
Not Available |
| UNII |
Q8BIH59O7H
|
| Synonyms |
Altretamine | Hemel | Hexamethylmelamine | Hexinawas | Hexalen | Hexastat |
|
| Chemical Information |
| Molecular Formula |
C9H18N6 |
| CAS Registry Number |
645-05-6 |
| SMILES |
CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Bone marrow failure | 01.03.03.005 | - | - | |
|
|
|
